Table 1 Baseline characteristics of study patients
Characteristic | Patients (n = 84) |
|---|---|
Age, mean (range; 95% CI) | 55 (18–85; 52–59) |
Gender, n (%) | |
 Male | 58 (69) |
 Female | 26 (31) |
Cardiovascular risk factors, n (%) | |
 Arterial hypertension | 37 (44) |
 Hypercholesterinemia | 21 (25) |
 Cardiac family history | 15 (18) |
 Smoking status | 32 (38) |
 Diabetes mellitus | 11 (13) |
 Adipositas | 12 (14) |
Laboratory parameters, median (IQR) | |
 Creatinine (mg/dL) | 0.89 (0.78–1.04) |
 GFR (mL/min) | 89 (75–101) |
Prior medical history, n (%) | |
 Chronic heart failure | 26 (31) |
  NYHA I | 10 (38) |
  NYHA II | 14 (54) |
  NYHA III | 2 (8) |
  NYHA IV | 0 (0) |
 Atrial fibrillation | 13 (15) |
  Paroxysmal | 8 (10) |
  Persistent | 3 (4) |
  Permanent | 2 (2) |
 Coronary artery disease | 26 (31) |
  1 vessel disease | 10 (12) |
  2 vessel disease | 3 (4) |
  3 vessel disease | 13 (15) |
 Past history of myocardial infarction | 17 (20) |
 Valvular heart disease | 31 (37) |
 Chronic kidney disease | 7 (8) |
 COPD | 7 (8) |
 Asthma | 6 (7) |
 Pneumonia | 2 (2) |
 Pulmonary hypertension | 1 (1) |
 Cancer | 7 (8) |
Medication, n (%) | |
 ACE-inhibitor/AT1-receptor antagonist | 43 (51) |
 Beta blocker | 43 (51) |
 Aldosterone antagonist | 15 (18) |
 Calcium antagonist | 18 (21) |
 Diuretics | 45 (54) |
 Acetylsalicylic acid | 32 (38) |
 Thienopyridines | 9 (11) |
 OAC/NOAC | 14 (17) |
 Statin | 34 (40) |